ACCF/AHA Advises Docs to Apply 'Careful Clinical Judgment' in PGx-Guided Administration of Plavix
July 07, 2010
ACCF/AHA Advises Docs to Apply 'Careful Clinical Judgment' in PGx-Guided Administration of Plavix
An ACCF/AHA panel has alerted doctors to evidence gaps regarding the clinical utility of genetic testing to administer Plavix, but not all cardiologists agree with the group's recommendations.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- AutoGenomics Gets FDA Clearance for CYP2C19 Test, But Cannot Mention Plavix PGx
October 27, 2010 / Pharmacogenomics Reporter - Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
November 2, 2011 / Pharmacogenomics Reporter - Celera Will Add to Quest's MDx Capabilities; But Reimbursement Questions Cloud Revenue Contribution
March 23, 2011 / Pharmacogenomics Reporter - New Data on CYP2C19 Loss-of-Function Alleles Questions Impact of Plavix PGx Testing
September 1, 2010 / Pharmacogenomics Reporter - FDA Issues Boxed Warning for CYP2C19-Linked Poor Metabolism of Plavix
March 17, 2010 / Pharmacogenomics Reporter